- Ocrelizumab - long-term efficacy and safety in real-world clinical practice in patients with relapsing-remitting multiple sclerosis2022 | Second Faculty of Medicine
- Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study2008 | First Faculty of Medicine
- Ofatumumab - a highly effective therapy for relapsing-remitting multiple sclerosis available in the first line2022 | Faculty of Medicine in Hradec Králové
- Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study2008 | First Faculty of Medicine
- Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review2017 | First Faculty of Medicine
- Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study2016 | First Faculty of Medicine
- Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis2014 | First Faculty of Medicine
- Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis2021 | Publication without faculty affiliation
- Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years : A Longitudinal Study2013 | First Faculty of Medicine
- The Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a double blind active extension of the multicentre, randomised, double-blind, parallel-group placebo-controlled studyPublication without faculty affiliation
- Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.2008 | Central Library of Charles University
- Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.2008 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM2015 | First Faculty of Medicine
- Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study2020 | First Faculty of Medicine
- Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years2020 | First Faculty of Medicine
- Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis2017 | First Faculty of Medicine
- Alemtuzumab in the therapy of patients with relapsing-remitting multiple sclerosis2016 | First Faculty of Medicine
- Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies2020 | First Faculty of Medicine
- Treatment of relapsing-remitting multiple sclerosis2008 | First Faculty of Medicine
- Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies2017 | First Faculty of Medicine
- Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study2014 | First Faculty of Medicine
- Current possibilities and principles of pharmacotherapy in relapsing-remitting multiple sclerosis2014 | Publication without faculty affiliation
- The treatment of patient with relapsing-remitting multiple sclerosis2017 | Faculty of Medicine in Hradec Králové
- Intravenous immunoglobulin in relapsing-remitting multiple sclerosis - A dose-finding trial2008 | Second Faculty of Medicine
- Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis2017 | First Faculty of Medicine
- Subcutaneously delivered natalizumab for the treatment of highly active relapsing-remitting multiple sclerosis2022 | Faculty of Medicine in Hradec Králové
- No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study2017 | First Faculty of Medicine
- Dimethyl-fumarate in treating relapsing-remitting multiple sclerosis +12014 | Second Faculty of Medicine
- Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis2015 | First Faculty of Medicine